ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Nitto Denko plans to spend about $225 million to increase capacity in its oligonucleotide contract manufacturing business by early 2023. The Japanese firm says it will expand process and analytical development at the unit’s headquarters in Milford, Massachusetts. Nitto also says it will construct a new building and oligo production line. Future plans include spending a similar amount to expand capacity for the polymer support needed to make oligos.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter